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http://dx.doi.org/10.1016/j.ccr.2012.09.020SUMMARYIt is unclear how cancer cells coordinate glycolysis and biosynthesis to support rapidly growing tumors. We
found that the glycolytic enzyme phosphoglycerate mutase 1 (PGAM1), commonly upregulated in human
cancers due to loss of TP53, contributes to biosynthesis regulation in part by controlling intracellular levels
of its substrate, 3-phosphoglycerate (3-PG), and product, 2-phosphoglycerate (2-PG). 3-PG binds to and
inhibits 6-phosphogluconate dehydrogenase in the oxidative pentose phosphate pathway (PPP), while
2-PG activates 3-phosphoglycerate dehydrogenase to provide feedback control of 3-PG levels. Inhibition
of PGAM1 by shRNA or a small molecule inhibitor PGMI-004A results in increased 3-PG and decreased
2-PG levels in cancer cells, leading to significantly decreased glycolysis, PPP flux and biosynthesis, as
well as attenuated cell proliferation and tumor growth.INTRODUCTION
The Warburg effect in cancer cells consists of an increase in
aerobic glycolysis and enhanced lactate production, which
generates more ATPs more quickly than in normal cells that
overwhelmingly rely on oxidative phosphorylation (Kroemer
and Pouyssegur, 2008). In addition, tumor tissue traps more
glucose than normal tissue does because cancer cells use
elevated amounts of glucose as a carbon source for anabolicSignificance
The current understanding of theWarburg effect consists of an
between glycolysis and PPP/biosynthesis is based on a mode
and biosynthesis pathways as precursors. Our findings demon
metabolites 3-PG and 2-PG, which function as signaling mo
involved in PPP and biosynthesis, representing an additional lin
itor PGMI-004A exhibits promising efficacy and minimal toxic
leukemia cells, providing ‘‘proof of principle’’ for the developm
Canbiosynthesis of macromolecules. These include nucleotides,
amino acids, and fatty acids, to produce RNA/DNA, proteins,
and lipids, respectively, which are necessary for cell prolifera-
tion and to accommodate the rapidly growing tumors (Kroemer
and Pouyssegur, 2008). Interestingly, leukemia cells are also
highly glycolytic (Elstrom et al., 2004; Gottschalk et al.,
2004), despite the fact that such cells reside within the blood-
stream at higher oxygen tensions than cells in most normal
tissues.increase in aerobic glycolysis in cancer cells. The connection
l in which glycolytic intermediates can be diverted into PPP
strate that PGAM1 regulates the concentrations of glycolytic
lecules to directly affect the catalytic activity of enzymes
k between glycolysis, PPP, and biosynthesis. PGAM1 inhib-
ity in treatment of xenograft nude mice and human primary
ent of PGAM1 inhibitors as anticancer agents.
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3-PG Inhibits 6PGD and 2-PG Potentiates PHGDHDuring glycolysis, glycolytic intermediates including glucose-
6-phosphate (G6P) can be diverted into the pentose phosphate
pathway (PPP), which contributes to macromolecular biosyn-
thesis by producing reducing potential in the form of reduced
nicotinamide adenine dinucleotide phosphate (NADPH) and/or
ribose-5-phosphate (R5P), the building blocks for nucleotide
synthesis. NADPH is the most crucial metabolite produced by
the PPP, because NADPH not only fuels macromolecular
biosynthesis such as lipogenesis, but also functions as a crucial
antioxidant, quenching the reactive oxygen species (ROS)
produced during rapid proliferation of cancer cells. Glycolysis
and glutaminolysis supply the carbon input required for the
tricarboxylic acid cycle to function as a biosynthetic ‘‘hub’’ and
permit the production of other macromolecules including amino
acids and fatty acids (Cairns et al., 2011). Thus, cancer cells
appear to coordinate glycolysis and anabolism to provide an
overall metabolic advantage to cancer cell proliferation and
disease development. However, the detailed mechanisms
underlying this coordination remain largely unknown.
Phosphoglycerate mutase 1 (PGAM1) catalyzes the conver-
sion of 3-phosphoglycerate (3-PG) to 2-phosphoglycerate
(2-PG) during glycolysis. PGAM1 regulates a unique step in
glycolysis, and most of the glycolytic intermediates that are
used as precursors for anabolic biosynthesis are upstream of
this step. In many cancers, including hepatocellular carcinoma
and colorectal cancer, PGAM1 activity is increased compared
to that in the normal tissues (Liu et al., 2008; Ren et al., 2010).
PGAM1 gene expression is believed to be upregulated due to
loss of TP53 in cancer cells because TP53 negatively regulates
PGAM1 gene expression (Corcoran et al., 2006; Tennant et al.,
2009, 2010). Here, we study the role of PGAM1 in the coordina-
tion of glycolysis and anabolic biosynthesis, as well as themech-
anism by which PGAM1 promotes cancer cell proliferation and
tumor growth.
RESULTS
PGAM1 Controls Intracellular 3-PG and 2-PG Levels
and Is Important for Cancer Cell Glycolysis, Anabolic
Biosynthesis, Proliferation, and Tumor Growth
To better understand how cancer cells coordinate glycolysis and
anabolic biosynthesis, we examined the effects of targeted
downregulation of the glycolytic enzyme PGAM1. Stable knock-
down of PGAM1 in lung cancer H1299, breast cancer MDA-
MB231, acute myeloid leukemia Molm14, and head and neck
cancer 212LN cells resulted in decreased PGAM1 activity (Fig-
ure S1 available online). We next performed Global Metabolic
Profiling (Metabolon) using cell lysate samples of parental
H1299 cells and cells with stable knockdown of PGAM1. The
results indicate that PGAM1 knockdown results in altered intra-
cellular concentrations of 118 biochemicals (61 upregulated and
57 downregulated) with p < 0.05 using Welch’s t-tests. Among
these biochemicals, we observed that the PGAM1 substrate
3-PG levels are increased in PGAM1 knockdown compared to
control cells (Tables S1 and S2). In consonance with this obser-
vation, we found that attenuation of PGAM1 by shRNA in diverse
cancer cells leads not only to increased 3-PG (Figure 1A), but
also decreased 2-PG (Figure 1B) levels compared to corre-
sponding control cells harboring an empty vector (detailed586 Cancer Cell 22, 585–600, November 13, 2012 ª2012 Elsevier Incdata are shown in Table S3). The intracellular levels of 3-PG
and 2-PG determined using different methods are comparable
(Figures S1B and S1C). In addition, stable overexpression of
PGAM1 in 3T3 cells results in increased 2-PG and decreased
3-PG levels, compared to control parental 3T3 cells (Figure S1D).
These results suggest a crucial role for PGAM1 controlling the
metabolite levels of its substrate 3-PG and product 2-PG in
cancer cells.
We next examined the role of PGAM1 in cancer cell metabo-
lism. We found that, compared to vector control cells, stable
knockdown of PGAM1 results in a decreased glycolytic rate (Fig-
ure 1C) and lactate production (Figure 1D), as well as reduced
glucose-dependent biosynthesis of RNA and lipids, accompa-
nied by reduced NADPH/NADP+ ratio (Figures 1E–1G, respec-
tively). Because the PPP produces NADPH and R5P to con-
tribute to macromolecular biosynthesis, we next examined
whether PGAM1 contributes to PPP flux. Indeed, we found
that oxidative PPP flux is reduced in PGAM1 knockdown
compared to control vector cells (Figure 1H). Interestingly, atten-
uation of PGAM1 in cancer cells does not affect glucose uptake
rate (Figure S1E), intracellular ATP levels (Figure 1I), or O2
consumption rate (Figure 1J) in either the presence or absence
of ATP synthase inhibitor oligomycin. These results suggest
that downregulation of PGAM1 attenuates glycolysis, PPP and
biosynthesis, but does not significantly affect glucose uptake
or intracellular ATP levels.
In addition, we found that stable knockdown of PGAM1 results
in decreased cell proliferation in diverse human cancer and
leukemia cells (Figure 1K). Moreover, we performed a xenograft
experiment in which nude mice were subcutaneously injected
with control H1299 cells harboring an empty vector on the left
flank and PGAM1 knockdown H1299 cells on the right flank (Fig-
ure 1L, left). The mice were monitored for tumor growth over
6 weeks. The masses of tumors derived from PGAM1 knock-
down H1299 cells were significantly reduced compared to those
of tumors formed by vector control cells (Figure 1L, right).
PGAM1 Knockdown Results in Elevated Levels of 3-PG,
which Binds to and Inhibits 6PGD by Competing with Its
Substrate, 6-PG
We next explored the molecular mechanism by which PGAM1
regulates the PPP. Our data suggest that the abnormally
high levels of 3-PG in PGAM1 knockdown cells may be ac-
counted for inhibition of oxidative PPP flux (Figure 1). To test
this hypothesis, we examined the effect of 3-PG on glucose-
6-phosphate dehydrogenase (G6PD), the first and most impor-
tant enzyme of the oxidative PPP, which produces NADPH,
and 6-phosphogluconate dehydrogenase (6PGD), an enzyme
that also produces NADPH while converting 6-phosphogluco-
nate into ribulose 5-phosphate in the presence of NADP+. We
performed in vitro 6PGD and G6PD assays in the presence of
increasing concentrations of 3-PG. Physiologic concentrations
of 3-PG in human cells are reported to be approximately 50–
80 mM (Feig et al., 1971; Minakami et al., 1964; Mulquiney and
Kuchel, 1999). As shown in Table S3, we determined that, in
H1299, MDA-MB231, and Molm14 cells, the 3-PG levels are
approximately 60–80 mM in control vector cells and 200–
300 mM in PGAM1 knockdown cells, while the 3-PG concentra-
tions are approximately 160 mM and 310 mM in 212LN control.
Figure 1. PGAM1 Controls Intracellular 3-PG and 2-PG Levels in Cancer Cells and Is Important for Glycolysis, Anabolic Biosynthesis, Cell
Proliferation, and Tumor Growth
(A and B) Intracellular concentrations of 3-PG and 2-PG were determined in diverse PGAM1 knockdown cancer cells and compared to control cells. Detailed
concentrations are listed in Table S3.
(C–J) H1299 cells with stable knockdown of PGAM1 and control cells harboring an empty vector were tested for glycolytic rate (C), lactate production (D), RNA
biosynthesis (E), lipogenesis (F), NADPH/NADP+ ratio (G), and oxidative PPP flux (H). The intracellular ATP levels (I) and oxygen consumption rate (J) in the
presence or absence of 100 nM oligomycin (ATP synthase inhibitor) were also tested.
(K) Cell proliferation rates were determined by cell counting in diverse human cancer (H1299, 212LN, andMDA-MB231) and leukemia (KG1a, Molm14, and K562)
cells with stable knockdown of PGAM1, which were normalized to the corresponding control cells harboring an empty vector.
(L) Stable knockdown of PGAM1 by shRNA attenuates tumor growth potential of H1299 cells in xenograft nude mice. Left: Dissected tumors (indicated by red
arrows) in a representative nudemouse and expression of PGAM1 in tumor lysates are shown. Right: PGAM1 knockdown cells show significantly reduced tumor
formation in xenograft nude mice compared to cells harboring empty vector control (p values were determined by a two-tailed paired Student’s t test).
The error bars represent mean values ± SD from three replicates of each sample (*0.01 < p < 0.05; **0.001 < p < 0.01; ***p < 0.001). See also Figure S1 and
Tables S1–S3.
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Figure 2. Attenuation of PGAM1 Results in Increased Intracellular Levels of 3-PG, which Binds to and Inhibits 6PGD by Competing with
Its Substrate 6-PG
(A and B) Enzyme activity of 6PGD in H1299 cell lysates (A) or recombinant 6PGD (r6PGD) (B) was determined in the presence of increasing concentrations
of 3-PG. Relative 6PGD activity was normalized to the control samples without 3-PG treatment. 3-PG levels in control H1299 cells with empty vector and
PGAM1 knockdown are 62.5 ± 10.8 mM and 256 ± 41.9 mM, respectively. The error bars represent mean values ± SD from three replicates of each sample
(**0.001 < p < 0.01; ***p < 0.001).
(C) Thermal shift melting curves of 6PGD and 3PG. Thermal shift assay was performed to examine the protein (6PGD) and ‘‘ligand’’ (3PG) interaction. Change of
melting temperature (Tm) in a dose-dependent manner at concentrations from 100 mM to 25 mM demonstrates that 3-PG directly binds to the protein. Kd for
6PGD-3-PG interaction was determined to be 460 ± 40 mM.
(D) The Dixon plot shows that 3-PG inhibits 6PGD and the dissociation constant (Ki) was determined.
(E) The Lineweaver-Burk plot shows that 3-PG functions as a competitive inhibitor of 6PGD.
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3-PG Inhibits 6PGD and 2-PG Potentiates PHGDHand PGAM1 knockdown cells, respectively. Thus, we next
examined the effects of increasing concentrations of 3-PG on
G6PD and 6PGD enzyme activities according to the aforemen-
tioned physiologic 3-PG levels in tumor cells.
We found that treatment with 3-PG concentrations analogous
to those in PGAM1 knockdown H1299 cells (250 mM) results in
decreased enzyme activity of 6PGD (Figure 2A) in H1299 cell
lysates or recombinant 6PGD (r6PGD) (Figure 2B), whereas the
physiologic 3-PG concentrations determined in control H1299
cells (60 mM) do not significantly affect 6PGD enzyme activity
in both experiments. In control experiments, treatment with
increasing concentrations of 3-PG did not significantly affect
G6PD activity in H1299 cell lysates or rG6PD activity (Fig-
ure S2A). In addition, 2-PG did not affect 6PGD enzyme activity
in H1299 cell lysates or r6PGD activity (Figure S2B). These
results suggest that abnormally high levels of 3-PG, as in
PGAM1 knockdown cells, may selectively and directly inhibit
6PGD but not G6PD.
To examine whether 3-PG binds to and inhibits 6PGD, we
performed a thermal melt shift assay to examine the interaction
of protein (6PGD) and ‘‘ligand’’ (3-PG). Incubation of increasing
concentrations of 3-PG raises 6PGD melting temperature (Tm)
in a dose-dependent manner, suggesting that 3-PG directly
binds to the protein (Figure 2C). The Kd value for protein-
‘‘ligand’’ interaction was calculated to be 460 ± 40 mM. More-
over, we performed kinetics studies on the inhibition of 6PGD
by 3-PG. As shown in Figure 2D, the Dixon plot indicates that
3-PG binds and inhibits 6PGD. The inhibition constant (Ki) was
determined to be 489 ± 13 mM, in agreement with the Kd
determined.
We next determined the intracellular concentration of 6-PG in
H1299, MDA-MB231, and 212LN cells to be 34.9 ± 2.1 mM,
37.6 ± 0.7 mM, and 24.9 ± 0.4 mM, respectively. We performed
additional enzyme kinetics assays to test whether 3-PG at a
concentration analogous to that in PGAM1 knockdown H1299
cells (250 mM) functions as a competitive or noncompetitive
inhibitor of 6PGD in the presence of physiologic concentrations
of 6-PG (35 mM). As shown in Figure 2E, the Lineweaver-Burk
plot demonstrates that 3-PG functions as a competitive inhibitor
of 6PGD. Because the Kd value for protein (6PGD)-ligand (6-PG)
interaction was calculated to be 37 ± 3 mM in a thermal melt shift
assay (Figure 2F), these combined data suggest that at physio-
logic concentrations, 3-PG (60–80 mM) cannot effectively
compete with 6-PG (35 mM) to inhibit 6PGD in cancer cells;
however, upon attenuation of PGAM1, elevated cellular 3-PG
levels (250–300 mM) result in reduced 6PGD enzyme activity.
To further understand the structural properties of 3-PG-medi-
ated inhibition of 6PGD, we crystallized the apo-form of 6PGD
(1.39 A˚), which was also soaked with 3-PG to obtain the 3-PG-
bound form of 6PGD (1.53 A˚) (Table S4). The Fo-Fc density anal-
ysis revealed that the electron density of 3-PGwas located in the
active site of the 3-PG-bound 6PGD structure (Figure 3A) but not
in the apo-6PGD structure (Figure 3B). 3-PG interacts with
several residues (Y191, T262, R287, R446) in the active site of(F) Thermal shift melting curves of 6PGD and 6PG. Thermal shift assay was perf
melting temperature (Tm) in a dose-dependent manner at concentrations from 5 m
6PG interaction was determined to be 37 ± 3 mM.
See also Figure S2.
Can6PGD that are important for substrate binding and enzymatic
activity of 6PGD (Li et al., 2006) (Figure 3A). Different conforma-
tions were observed for Arg 446 and His 452 in the 3-PG-bound
6PGD structure compared to the apo-form 6PGD structure (Fig-
ure 3C). An alignment of three different 6PGD structures with
bound NADP, 6-PG, and 3-PG shows an overlap of 3-PG and
6-PG in the active site (Figure 3D). Together, these results
demonstrate that 3-PG directly binds to 6PGD and inhibits
6PGD enzyme activity by competing with the cognate substrate
6-PG, representing a molecular mechanism to explain how
PGAM1, as a glycolytic enzyme, contributes to the regulation
of the oxidative PPP and consequently anabolic biosynthesis.
Rescue of Reduced 2-PG Levels in PGAM1 Knockdown
Cells Results in Decreased 3-PG Levels by Activating
3-PG Dehydrogenase
To examine the effect of decreased 2-PG levels on cancer cell
metabolism, we treated the aforementioned PGAM1 knockdown
cancer cells with a cell permeable agent, methyl-2-PG, which
converts to 2-PG in cells. We verified that in diverse PGAM1
knockdown cancer cells, treatment with methyl-2-PG results in
increased 2-PG cellular levels comparable to those in the corre-
sponding control vector cells (Figure 4A). We also observed that
methyl-2-PG treatment rescues the reduced lactate production
(Figure 4B) but has no significant effect on intracellular ATP levels
(Figure S3A) in H1299 cells with stable knockdown of PGAM1
compared to control vector cells. This result suggests that
rescuing cellular 2-PG levels reverses the inhibitory effect of
PGAM1 knockdown on glycolysis and allows downstream
glycolytic reactions to resume and ultimately produce lactate.
However, such rescued glycolytic activity does not affect ATP
levels, which is consistent with our previous observation (Figures
1I and 1J).
Surprisingly, we also found that methyl-2-PG treatment
rescues the decreased oxidative PPP flux and biosynthesis of
RNA and lipids, as well as partially restores the reduced cell
proliferation in H1299 PGAM1 knockdown cancer cells com-
pared to the corresponding control vector cells (Figures 4C–
4F). Similar results were obtained using MDA-MB231 vector
and PGAM1 knockdown cells (Figures S3B–S3E). These data
suggest that the increased 2-PG levels in PGAM1 knockdown
cells provide a feedback mechanism to rescue the abrogated
PPP and anabolic biosynthesis upstream of PGAM1.
We tested this hypothesis by examining the effect of rescued
2-PG levels on 3-PG concentrations in PGAM1 knockdown cells.
We found that treatment with methyl-2-PG results in decreased
3-PG concentrations in diverse PGAM1 knockdown cells to
levels that are comparable to the 3-PG concentrations in the cor-
responding control vector cells (Figure 5A). These results further
suggest that PGAM1 controls 2-PG levels in cancer cells, which
contributes to PGAM1-dependent coordination of glycolysis and
anabolic biosynthesis by adjusting 3-PG levels.
We next determined the molecular mechanism underlying
2-PG-dependent feedback regulation of intracellular 3-PG levels.ormed to examine the protein (6PGD) and ligand (6PG) interaction. Change of
M to 5 mM demonstrates that 6-PG directly binds to the protein. Kd for 6PGD-
cer Cell 22, 585–600, November 13, 2012 ª2012 Elsevier Inc. 589
Figure 3. Co-Crystallization Analysis of 3-PG-Mediated Inhibition of 6PGD
(A) Stereo view of the Fo-Fc electron density map contoured at 3.0 s around 3-PG. The Fo-Fc densitymap is shown as bluemesh. Residues of 6PGD interact with
3-PG are shown in stick.
(B) Upper top: Stereo view of the unbiased Fo-Fc electron density map contoured at 3.0 s around 3PG. The Fo-Fc density map is shown as blue mesh. Residues
interacting with 3-PG are shown in stick. Lower top: Stereo view of the 2Fo-Fc electron density map of 6PGD apo-form contoured at 1.2 s at 3-PG binding pocket
in the same orientation as in Figure 3A. The 2Fo-Fc density map is shown as blue mesh. Upper bottom: Stereo view of the 2Fo-Fc electron density map of 6PGD-
3-PG complex contoured at 1.2 s at 3-PG binding pocket in the same orientation as in Figure 3A. The 2Fo-Fc density map is shown as blue mesh. Lower bottom:
Stereo view of simulated-annealing omit map contoured at 0.8 s around 3-PG. The omit density map is shown as blue mesh.
(C) Structure comparison of the 6PGD apo-form (wheat) and the 6PGD-3-PG complex (green). Arg 446 and His 452 in the 6PGD-3-PG complex structure show
different conformation.
(D) Surface electrostatic potential of the substrate binding pocket of 6PGD. The bound 3-PG (pink) competes with 6-PG (blue) but not NADP (yellow) in the active
site. The model was built by aligning structures of 6PGD-NADP (PDB number: 2JKV), 6PGD-6-PG (PDB number: 3FWN), and 6PGD-3PG.
See also Table S4.
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3-PG Inhibits 6PGD and 2-PG Potentiates PHGDHBesides conversion to 2-PG catalyzed by PGAM1 in glycolysis,
3-PG also serves as a precursor for serine synthesis and can
be converted to 3-phosphohydroxypyruvate (pPYR) by 3-PG
dehydrogenase (PHGDH). Because PGAM1 activity is attenu-
ated in PGAM1 knockdown cells, it is possible that the rescued
cellular 2-PG levels by methyl-2-PG treatment decreases 3-PG
levels by activating PHGDH.We tested this hypothesis by exam-
ining the effect of 2-PG on PHGDH activity and we used PGAM1
knockdown cells to exclude the endogenous PGAM1 effect on 3-
PG and 2-PG in the PHGDH enzyme activity reactions. Indeed,
we found that treatment with 2-PG concentrations equivalent to
those determined in control H1299 cells (45 mM) or methyl-2-
PG treated PGAM1 knockdown cells (60 mM) results in higher590 Cancer Cell 22, 585–600, November 13, 2012 ª2012 Elsevier IncPHGDH enzyme activity in H1299 PGAM1 knockdown cell
lysates (Figure 5B, left). Similar results were obtained by treating
212LN PGAM1 knockdown cell lysates with increasing concen-
trations of 2-PG (Figure 5B, right). Moreover, treatment with
increasing concentrations of 2-PG results in increased enzyme
activity of recombinant PHGDH (rPHGDH) (Figure 5C). In con-
trast, 2-PG concentrations that correspond to those determined
in PGAM1 knockdown cells (15 mM) did not significantly affect
PHGDH activity. Together, these studies reveal a feedback
mechanism by which cellular 2-PG levels contribute to control
of 3-PG levels in cells through regulation of PHGDH.
In addition, we found that stable knockdown of PGAM1 results
in significantly decreased serine biosynthesis, while treatment.
Figure 4. Rescue of Reduced 2-PG Levels in PGAM1 Knockdown Cells Reverses the Phenotypes due to Attenuation of PGAM1
(A) 2-PG levels in diverse cancer cells with stable knockdown of PGAM1 were determined in the presence and absence of cell-permeable methyl-2-PG.
(B–F) H1299 cells with stable knockdown of PGAM1 were tested for lactate production (B), oxidative PPP flux (C), biosynthesis of RNA (D) and lipids (E),
and proliferation (F) in the presence and absence of methyl-2-PG.
The error bars represent mean values ± SD from three replicates of each sample (*0.01 < p < 0.05; **0.001 < p < 0.01; ***p < 0.001). See also Figure S3.
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3-PG Inhibits 6PGD and 2-PG Potentiates PHGDHwith methyl-2-PG rescues the phenotype (Figure 5D). Moreover,
shRNA-mediated knockdown of PHGDH (Figure 5E) does not
affect rescued 2-PG levels in PGAM1 knockdown cells upon
treatment with methyl-2-PG, while PHGDH knockdown abol-
ishes the methyl-2-PG-dependent decrease of the elevated
3-PG levels in H1299 PGAM1 knockdown cells (Figure 5F; leftCanand right, respectively). These data support our hypothesis
that PGAM1 controls 2-PG levels to regulate PHGDH, which
consequently regulates 3-PG levels by diverting 3-PG in serine
biosynthesis. Furthermore, knockdown of PHGDH in PGAM1
stable knockdown cells reverses the methyl-2-PG treatment
dependent rescue of oxidative PPP flux as well as biosynthesiscer Cell 22, 585–600, November 13, 2012 ª2012 Elsevier Inc. 591
Figure 5. Rescue of Reduced 2-PG Levels due to PGAM1 Attenuation Results in Decreased 3-PG Levels by Activating PHGDH
(A) 3-PG levels in diverse cancer cells with stable knockdown of PGAM1 were determined in the presence and absence of methyl-2-PG.
(B andC) Enzyme activity of PHGDH in PGAM1 knockdownH1299 (B; left) or 212LN (B; right) cell lysates and recombinant PHGDH (rPHGDH) (C) were determined
in the presence of increasing concentrations of 2-PG. Relative enzyme activity was normalized to the control samples without 2-PG treatment. 2-PG levels in
control H1299 cells with empty vector and PGAM1 knockdown cells are 46.2 ± 10.2 mM and 15.0 ± 14.1 mM, respectively, while 2-PG levels in 212LN cells with
empty vector and stable knockdown of PGAM1 are 58.3 ± 20.1 mM and 17.8 ± 14.4 mM, respectively.
(D) Serine biosynthesis rate of H1299 cells with stable knockdown of PGAM1 was determined by measuring 14C incorporation into serine from 14C-glucose in the
presence and absence of methyl-2-PG. Relative serine biosynthesis was normalized to control cells harboring an empty vector without methyl-2-PG treatment.
Cancer Cell
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Cancer Cell
3-PG Inhibits 6PGD and 2-PG Potentiates PHGDHof serine, lipids, and RNA (Figures 5G and 5H, respectively).
These data together suggest that, besides being a glycolytic
metabolite, 2-PG may also signal through PHGDH to provide
regulation of PPP flux and anabolic biosynthesis, at least in
part by regulating 3-PG levels.
PGAM1 Enzyme Activity Strikes a Balance between
3-PG and 2-PG Levels, which Coordinates Glycolysis
and Biosynthesis to Promote Cancer Cell Proliferation
To study the role of PGAM1 enzyme activity in cancer metabo-
lism and tumor development, we screened and developed
a small molecule inhibitor of PGAM1. Currently the only reported
PGAM1 inhibitor is MJE3, which specifically inhibits PGAM1
activity exclusively in intact cells, probably by targeting the
active site of PGAM1 with certain modifications in vivo (Evans
et al., 2005, 2007). We designed a screening strategy using
coupled PGAM1 and enolase assays and identified three lead
small molecule compounds, including alizarin, as PGAM1 inhib-
itors from a library of 2,000 US Food and Drug Adminstration-
approved small molecule compounds (Figures 6A, S4A, and
S4B). We focused on 1,2-dihydroxyanthraquinone, a.k.a. alizarin
(C14H8O4) (Figure 6B, top), which is an organic compound that is
historically important as a prominent dye, originally derived from
the roots of plants of the Madder genus. Treatment with alizarin
results in decreased proliferation of human leukemia KG1a cells
in a dose-dependent manner (Figures S4C and S4D).
We next identified Alizarin Red S (Figure 6B, middle) as a more
potent PGAM1 inhibitor from a group of alizarin derivatives
(Figures S4E and S4F). We designed a group of Alizarin Red S
derivativesbyaddinghydrophobic groups throughasulfonamide
bond (Figure S5A). Among these compounds, we focused on
PGAM1 inhibitor 004A (PGMI-004A) (Figure 6B, bottom), which,
although less potent than Red S in vitro, demonstrates enhanced
potency to inhibit PGAM1 in leukemia KG1a cells compared to
its parental compounds (Figures S5B and S5C). This may be
due to the fact that PGMI-004A ismore hydrophobic than alizarin
and alizarin red S, which confers better cell permeability.
PGMI-004A inhibits PGAM1 with an IC50 of 13.1 mM (Fig-
ure 6C) and the Kd value of the PGMI-004A-PGAM1 interaction
was determined to be 7.2 ± 0.7 mM from fluorescence-based
binding assay (Figure 6D). In a competitive binding assay where
PGMI-004A was incubated with recombinant PGAM1 proteins in
the presence of different concentrations of PGAM1 substrate
3-PG, we found that increasing concentrations of 3-PG caused
an increase in the fluorescence intensity from PGMI-004A-
unbound form of PGAM1 in the presence of different concentra-
tions of PGMI-004A, but not in the absence of PGMI-004A
(Figure 6E). This suggests that PGMI-004A may allosterically
modulate the enzyme activity of PGAM1. The Ki value was deter-
mined to be 3.91 ± 2.50 mM using Dixon plot analysis (Figure 6F).
In addition, we performed a thermal melt shift assay to examine
the interaction of protein (PGAM1) and ligand (PGMI-004A).(E) Western blot result shows shRNA-mediated knockdown of PHGDH in H1299 c
PG treatment.
(F) 2-PG (left) and 3-PG (right) levels in PGAM1 knockdown cells upon PHGDH k
(G andH) PGAM1 stable knockdown cells treatedwith or without shRNA targeting
RNA (H; left, middle, and right, respectively) in the presence and absence of me
The error bars represent mean values ± SD from three replicates of each sample
CanIncubation of increasing concentrations of PGMI-004A raises
PGAM1 melting temperature (Tm) in a dose-dependent manner,
suggesting that PGMI-004A directly binds to the protein (Fig-
ure 6G). The Kd value for protein-ligand interaction was calcu-
lated to be 9.4 ± 2.0 mM. Together, these results suggest that
PGMI-004A directly binds to PGAM1 and inhibits its enzyme
activity.
We found that inhibition of PGAM1 activity by PGMI-004A
treatment results in decreased 2-PG and increased 3-PG levels
in H1299 cells, which could be rescued by treatment with
methyl-2-PG (Figure 7A). Moreover, treatment with PGMI-004A
results in significantly reduced lactate production that was
rescued bymethyl-2-PG treatment (Figure 7B), but has no signif-
icant effect on intracellular ATP levels (Figure 7C). In consonance
with these observations, the rescued lactate production due to
methyl-2-PG treatment was abolished when enolase was
knocked down or inhibited by specific inhibitor NaF in PGMI-
004A treated cells (Figure S5D). These results also suggest
that rescued 2-PG derived from methyl-2-PG is metabolized
by cells to restore the decreased glycolysis due to PGAM1 inhi-
bition in cancer cells. We also found that PGMI-004A treatment
results in decreased oxidative PPP flux (Figure 7D) and
NADPH/NADP+ ratio (Figure 7E), aswell as reduced biosynthesis
of lipids and RNA (Figures 7F and 7G, respectively) and cell
proliferation (Figure 7H) in H1299 cells. These phenotypes are
similar to those observed in PGAM1 knockdown cells, which
could be significantly rescued by treatment with methyl-2-PG,
suggesting that PGMI-004A targets PGAM1 to inhibit cancer
cell metabolism and proliferation.
In addition, we observed that PGMI-004A treatment results in
decreased cell proliferation of diverse human cancer and
leukemia cells (Figures 7I and 7J and S5E–S5H), but not control
human dermal fibroblasts (HDF), human foreskin fibroblasts
(HFF), human HaCaT keratinocyte cells and human melanocyte
PIG1 cells (Figures 7K and S5I), suggesting minimal non-specific
toxicity of PGMI-004A in normal, proliferating human cells.
Targeting PGAM1 by PGMI-004A Treatment Inhibits
Cancer Cell Proliferation and Tumor Growth and Alters
3-PG and 2-PG Levels in Primary Leukemia Cells from
Patients, Leading to Attenuated Leukemia Cell
Proliferation
We next performed an in vivo drug treatment experiment. Initial
toxicity studies by chronic injection of PGMI-004A to nude
mice for 4 weeks revealed that 100 mg/kg/day administered
intraperitoneally is a well-tolerated dose. In addition, continuous
treatment with PGMI-004A (100 mg/kg/day) for 7 days did not
result in significant alteration in body weight, complete blood
cell counts, or hematopoietic properties of nude mice (Table
S5). Histopathologic analyses revealed that no notable differ-
ences between the vehicle-treated and PGMI-004A-treated
groups were evident (Figures S6A–S6D). We performedells with stable knockdown of PGAM1 in the presence or absence of methyl-2-
nockdown were determined in the presence and absence of methyl-2-PG.
PHGDHwere tested for PPP flux (G) aswell as biosynthesis of serine, lipids and
thyl-2-PG.
(*0.01 < p < 0.05; **0.001 < p < 0.01; ***p < 0.001; n.s., not significant).
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Figure 6. Identification and Characterization of a Small Molecule PGAM1 Inhibitor, PGMI-004A
(A) Schematic representation of the primary and secondary screening strategies to identify lead compounds as PGAM1 inhibitors.
(B) Structure of alizarin and its derivatives alizarin red S and PGAM1 inhibitor (PGMI)-004A.
(C) PGMI-004A inhibits PGAM1 with an IC50 of 13.1 mM, which was determined by incubating purified human PGAM1 proteins with increasing concentrations of
PGMI-004A. The error bars represent mean values ± SD from three replicates of each sample.
(D) Kd value was determined as 7.2 ± 0.7 mM by incubating purified human PGAM1 proteins with increasing concentrations of PGMI-004A. The fluorescence
intensity (Ex: 280 nm, Em: 350 nm) from tryptophan was measured (Schauerte and Gafni, 1989).
(E) Competitive binding assay of PGMI-004Awith recombinant PGAM1 protein in the presence of increasing concentrations of PGAM1 substrate 3-PG. Increased
free PGAM1 was determined by an increase in fluorescence intensity.
(F) Dixon plot analysis of PGAM1 enzyme assay in the presence of different concentrations of PGMI-004A and 3-PG. The reaction velocity (v) was determined by
the rate of the decrease in fluorescence (ex: 340 nm, em: 460 nm) by NADH oxidation. Ki was determined to be 3.91 ± 2.50 mM.
(G) Thermal shift melting curves of PGAM1 and PGMI-004A. Thermal shift assay was performed to examine the protein (PGAM1) and ‘‘ligand’’ (inhibitor PGMI-
004A) interaction. Change of melting temperature (Tm) in a dose-dependent manner at concentrations from 2.5 mM to 80 mM demonstrates that PGMI-004A
directly binds to the protein. Kd for PGAM1-PGMI-004A interaction was determined to be 9.4 ± 2.0 mM.
See also Figure S4.
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as described (Hitosugi et al., 2009). Six days postinjection,
mice were divided into two groups (n = 8/group) and treated
with either PGMI-004A (100 mg/kg/day) or vehicle for 21 days.
We found that PGMI-004A treatment results in significantly
decreased tumor growth and size in treated mice compared
with mice receiving vehicle control (Figures 8A and 8B, respec-
tively; Figures S6E and S6F). Moreover, treatment with PGMI-
004A effectively inhibits PGAM1 enzyme activity in tumors in vivo
in resected tumors from xenograft nude mice (Figure S6G).
These combined data suggest that targeting PGAM1 by PGMI-
004A inhibits PGAM1 in vivo, and that this inhibition causes
specific toxicity to tumor cells.
We found that PGAM1 protein expression and enzyme activity
levels are commonly upregulated in primary leukemia cells
from diverse patients with acute myeloid leukemia (AML),
chronic myelogenous leukemia (CML), or acute B lymphoblastic
leukemia (B-ALL; n = 12), compared to control peripheral blood
cells from healthy donors (n = 4) (Figure 8C). We next found that,
consistent with our observations in cancer cell lines, inhibiting
PGAM1 by PGMI-004A treatment results in increased 3-PG
and decreased 2-PG levels in primary leukemia cells from
a representative patient with AML (Figure 8D). PGMI-004A treat-
ment also results in decreased cell viability and reduced PGAM1
activity and lactate production in the samples from seven (one
CML and six AML) out of eight patients with leukemia. Figures
8E, S6H, and S6I show results using samples from patients
with CML or AML as representatives, respectively. Moreover,
methyl-2-PG treatment rescues the decreased cell viability
(Figures 8F and 8G, left) and lactate production (Figure 8G, right)
in primary leukemia cells from representative patients with AML.
In addition, PGMI-004A treatment did not affect cell viability of
mononucleocytes in peripheral blood samples from two healthy
human donors (Figures 8H and S6J) and CD34+ cells isolated
from bone marrow samples from four healthy donors (Figures
8I and S6K), suggesting promising anticancer potential of
PGMI-004A with minimal toxicity to human blood cells. These
combined results of translational studies suggest that PGAM1
is a promising therapeutic target in the treatment of human
malignancies.
DISCUSSION
Our findings suggest that upregulation of PGAM1 by increased
gene expression in cancer cells provides a metabolic advantage
to cancer cell proliferation and tumor growth; PGAM1 coordi-
nates glycolysis and anabolic biosynthesis, at least in part by
controlling intracellular levels of its substrate 3-PG and product
2-PG (Figure 8J). Our results revealed a molecular mechanism
by which 3-PG inhibits 6PGD by directly binding to the active
site of 6PGD and competing with its substrate 6-PG. Attenuation
of PGAM1 results in abnormal accumulation of 3-PG, which in
turn inhibits 6PGD and consequently the oxidative PPP and
anabolic biosynthesis. Moreover, our findings suggest that
PGAM1 controls the intracellular levels of its substrate 3-PG
not only directly through substrate consumption, but also indi-
rectly by controlling levels of its product 2-PG. Physiologic
concentrations of 2-PG promote the enzyme activity of PHGDH,
which converts 3-PG to pPYR, reducing the cellular 3-PG levels.CanUpon attenuation of PGAM1, 2-PG is decreased to levels below
the physiologic concentrations, leading to decreased PHGDH
activity, which facilitates 3-PG accumulation. This represents
a regulatory mechanism by which 2-PG activates PHGDH to
provide feedback control of 3-PG levels. Thus, we suggest that
PGAM1 activity is upregulated in cancer cells to promote glycol-
ysis and keep the intracellular 3-PG levels low, which in turn
permits high levels of the PPP and biosynthesis to fulfill the
request of rapidly growing tumors. This is consistent with
previous report that expression of TP53 suppresses oxidative
PPP in cancer cells (Jiang et al., 2011). In addition, PGAM1
may also be responsible for maintaining the physiological levels
of 2-PG to sustain PHGDH activity, which diverts 3-PG from
glycolysis to serine synthesis and contributes to maintaining
relatively low levels of 3-PG in cancer cells.
Inhibition of PGAM1 by shRNA or treatment with a small mole-
cule inhibitor PGMI-004A results in altered glycolysis and
anabolic biosynthesis, and reduced cancer cell proliferation
and tumor growth. Interestingly, targeting PGAM1 does not
significantly affect intracellular ATP levels. Decreased ATP
production due to attenuated glycolysis in PGAM1 knockdown
cells may be compensated by alternative mechanisms other
than mitochondrial oxidative phosphorylation, or perhaps the
ATP consumption in PGAM1 knockdown cells is decreased
accordingly. Methyl-2-PG treatment rescues most of the afore-
mentioned phenotypes. Rescued 2-PG levels in cells with atten-
uated PGAM1 reversed decreased lactate production by
rescuing the glycolytic process downstream of PGAM1, as well
as reduced oxidative PPP flux and biosynthesis of RNA and
lipids, at least in part by decreasing elevated 3-PG levels.
However, methyl-2-PG treatment only partially rescues the
attenuated cell proliferation in PGAM1 knockdown cells or
cells treated with PGMI-004A. This result suggests that PGAM1
may contribute to cell proliferation in both 2-PG-dependent
and -independent manners.
The current understanding of the connection between glycol-
ysis and PPP/biosynthesis is based on a model in which glyco-
lytic intermediates can be diverted into PPP and biosynthesis
pathways as precursors. Our results show that the concentra-
tions of glycolytic metabolites such as 3-PG and 2-PG can
directly affect the catalytic activity of enzymes involved in PPP
and biosynthesis, which represents an additional link between
glycolysis, PPP, and biosynthesis. Metabolites have been sug-
gested to function as signaling molecules in the past. Examples
include AMP, which is an allosteric activator for AMP-activated
protein kinase (AMPK), a kinase that senses intracellular energy
levels (ATP/AMP ratio) (Shackelford and Shaw, 2009), and
glutamine, which activates leucine uptake, leading to mTOR
activation (Nicklin et al., 2009). We found that the cellular levels
of 3-PG and 2-PG, two key intermediates in glycolysis, have
additional regulatory impact on metabolic enzymes to affect
cell metabolism and consequently proliferation, which provides
an example to suggest that glycolytic metabolites could also
serve as signaling molecules to control cell metabolism and
cellular responses. Moreover, our findings also describe a feed-
back mechanism by which the product levels (2-PG) of a meta-
bolic enzyme (PGAM1) can regulate its substrate levels (3-PG)
by affecting an alternative enzyme (PHGDH) that is involved in
production of this substrate. Thus, this study showcases thecer Cell 22, 585–600, November 13, 2012 ª2012 Elsevier Inc. 595
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the intracellular levels of a particular metabolite may involve
diverse enzymes in different metabolic reactions, such that the
balance of the intracellular levels of various metabolites may
exert regulatory functions on enzymes in different pathways to
control cellular metabolism. Such a mechanism can be explored
for anticancer therapies.
Previous reports describe that targeting PGAM1 by a PGAM1-
derived inhibitory peptide or PGAM inhibitor MJE3 attenuates
cancer cell proliferation (Engel et al., 2004; Evans et al., 2005).
In consonance with these observations, our studies suggest
that protein expression and enzyme activity levels of PGAM1
are important for cancer cell proliferation and tumor growth.
Our compound PGMI-004A exhibits promising efficacy in the
treatment of xenograft nude mice in vivo with minimal toxicity,
as well as in diverse human cancer cells and primary leukemia
cells from human patients in vitro with no obvious off-target
effect and minimal toxicity to human cells. These translational
studies provide ‘‘proof of principle’’ to suggest anti-PGAM1 as
a promising therapy in clinical treatment of tumors that heavily
rely on the Warburg effect. However, the potential toxicity of
PGAM inhibitors in vivo to normal postmitotic, metabolically
active organs such as brain, liver, skeletal muscle, and heart,
all of which are glycolytic, remains undetermined. This warrants
further detailed toxicity and pharmacokinetics studies to
improve the proposed anti-PGAM1 therapy in cancer treatment.
EXPERIMENTAL PROCEDURES
Cellular Metabolites Extraction and Measurement
Cellular metabolites were extracted and spectrophotometrically measured as
described previously (Kauffman et al., 1969; Minakami et al., 1965) with some
modifications. To determine cellular concentration of 2-PG and 3-PG, 100 ml of
packed cell pellets were homogenized in 1.5 ml of hypotonic lysis buffer
(20 mM HEPES (pH 7.0), 5 mM KCl, 1 mM MgCl2, 5 mM DTT, and protease
inhibitor cocktail). The homogenates were centrifuged in a cold room at 4C
for 10 min at maximum speed, and the supernatants were applied to Amicon
Ultra tubes with 10KDa cut off filter (Millipore). The flow through containing the
metabolites was used for the measurement. NADH, ADP, and MgCl2 were
added to the flow through to final concentrations of 0.14 mM, 1 mM, and
50 mM, respectively. Recombinant LDH and PKM1 proteins were added to
final concentrations of 5 mg/ml and 10 mg/ml, respectively. Recombinant
enolase protein was added to a final concentration of 50 mg/ml to measure
cellular 2-PG. Once the reaction was initiated by enolase, a decrease in absor-
bance at 340 nm from NADH oxidation was measured by a DU800 spectro-
photometer (Beckman). After termination of the enolase reaction, recombinant
PGAM1 protein was added to a final concentration of 25 mg/ml and the
decrease in absorbance at 340 nm was immediately monitored to measure
cellular 3-PG. One hundred microliters of 2-PG and 3-PG (Sigma) diluted
with 1.5 ml of hypotonic lysis buffer were used as the standards.Figure 7. Inhibition of PGAM1 by PGMI-004A Reveals that PGAM1 Enzy
Coordination of Glycolysis and Biosynthesis to Promote Cancer Cell P
(A) 2-PG (left) and 3-PG (right) levels in H1299 cells treated with or without PGM
(B and C) Lactate production (B) and intracellular ATP levels (C) in H1299 cells trea
of methyl-2-PG.
(D and E) H1299 cells treated with or without PGMI-004A were tested for oxidati
(F–H) H1299 cells treated with or without PGMI-004A were tested for biosynthes
absence of methyl-2-PG.
(I–K) Cell viability of H1299 cells (I), diverse human leukemia cells (J) and control
viability was determined by trypan blue exclusion.
The error bars represent mean values ± SD from three replicates of each sample
See also Figure S5.
CanProtein Crystallization, Data Collection, and Structure
Determination
For protein crystallization, 6PGD was crystallized by using the hanging
drop vapor diffusion method. To soak in 3-PG, 0.2 ml of 5 mM 3-phosphoglyc-
erate acid were added into the mixture and incubated for 2 hr. The crystals
were then flash-frozen in liquid nitrogen with the same cryoprotectant
solution. Because a high concentration of 3-PG causes the crystal to crack,
a final 3-PG concentration of 833 mM was applied and an occupancy of
50% was obtained after refinement. For data collection, the crystal diffraction
data of 6PGD apo-form and 6PGD-3-PG complex were collected at the
macromolecular crystallography for life science beamline GM/CA-CAT
(23-ID-F) and NE-CAT (24-ID-E) respectively at the Advanced Photon Source,
Argonne National Laboratory. The data were processed with HKL2000 and
the scaled data were used for molecular replacement. For phasing, model
building and refinement, the structure of 6PGD apo-form was determined
by molecular replacement using Molrep in the CCP4 suite, with the protein
portion of the solved structure of 6PGD-6-PG as the search model (Protein
Data Bank [pdb] number: 3FWN) (Chen et al., 2010). The structure was then
refined by using Phenix (Haddadian et al., 2011). Manual rebuilding of the
model was carried out using the molecular graphics program COOT based
on electron density interpretation. Water molecules were incorporated into
the model if they gave rise to peaks exceeding 3s in Fo-Fc density maps.
The structure of the 6PGD-3-PG complex was also determined by molecular
replacement using Molrep with the solved structure of 6PGD apo-form as the
search model, and then refined by using Phenix. Manual rebuilding of
the model was carried out using the molecular graphics programs COOT.
The final structures of apo-form and 6PGD-3-PG complex were visualized
by using PyMol software.
Xenograft Studies
Approval of use of mice and designed experiments was given by the Institu-
tional Animal Care and Use Committee of Emory University. Nude mice
(Athymic Nude-Foxn1nu, female 6- to 8-week-old, Harlan) were subcutane-
ously injected with 10 3 106 H1299 cells harboring empty vector on the left
flank, and cells with stable knockdown of endogenous hPGAM1 on the right
flank, respectively. The tumors were harvested and weighed at the experi-
mental endpoint, and the masses of tumors (g) derived from cells with and
without stable knockdown of endogenous hPGAM1 in both flanks of each
mouse were compared. Statistical analyses were performed by comparison
in relation to the control group with a two-tailed paired Student’s t test. For
drug evaluation of PGMI-004A using xenograft mice, the drug was adminis-
tered by daily intraperitoneal injection at a dose of 100mg/kg from 6 days after
subcutaneous injection of H1299 cells on right flank of each mouse. Tumor
growth was recorded by measurement of two perpendicular diameters of
the tumors over a 3 week course using the formula 4p/3 3 (width/2)2 3
(length/2). The tumors were harvested and weighed at the experimental
endpoint. The masses of tumors (g) treated with vehicle control (DMSO:
PEG400:PBS at a ratio of 4:3:3) and PGMI-004A were compared and p values
were determined by a two-tailed Student’s t test.
Primary Tissue Samples from Patients with Leukemia and Healthy
Donors
Approval of use of human specimens was given by the Institutional Review
Board of Emory University School of Medicine. All clinical samples wereme Activity Is Important for Regulation of 3-PG and 2-PG Levels and
roliferation
I-004A were determined in the presence and absence of methyl-2-PG.
ted with or without PGMI-004A were determined in the presence and absence
ve PPP flux (D) and NADPH/NADP+ ratio (E).
is of lipids (F) and RNA (G), as well as cell proliferation (H) in the presence and
HDF cells (K) in the presence of increasing concentrations of PGMI-004A. Cell
(*0.01 < p < 0.05; ***p < 0.001; n.s., not significant).
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Institutional Review Board. Clinical information for the patients was obtained
from the pathologic files at Emory University Hospital under the guidelines
and with approval from the Institutional Review Board of Emory University
School of Medicine and according to the Health Insurance Portability and
Accountability Act. Only samples from patients that were not previously
treated with chemotherapy or radiation therapy were used. Mononuclear cells
were isolated from peripheral blood and bone marrow samples from patients
with leukemia or peripheral blood samples from healthy donors using
lymphocyte separation medium (Cellgro). Cells were cultured in RPMI 1640
medium supplemented with 10% fetal bovine serum and penicillin/strepto-
mycin and incubated with increasing concentrations of PGMI-004A for up
to 72 or 120 hr.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, five tables, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2012.09.020.
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(A and B) Tumor growth (A) and tumor size (B) in xenograft nude mice injected wi
004A and the control group treated with vehicle control. p values were determin
(C) PGAM1 protein expression (lower) and enzyme activity (upper) levels were e
CML, or B-ALL and compared to control peripheral blood cells from healthy don
(D) Effect of PGMI-004A treatment on 3-PG (left) and 2-PG (right) levels in huma
sentative patient with AML.
(E) Effect of PGMI-004A treatment on cell viability (left), PGAM1 activity (middle)
sentative patient with CML.
(F and G) Effect of methyl-2-PG treatment on decreased cell viability (F; G left) a
cells from patients with AML.
(H and I) PGMI-004A shows no toxicity in treatment (120 hr) of peripheral blood
sentative healthy human donors.
(J) Proposed model: role of PGAM1 in cancer cell metabolism.
Left: PGAM1 activity is upregulated in cancer cells to promote glycolysis and kee
and biosynthesis to fulfill the request of rapidly growing tumors. PGAM1 also ma
3-PG from glycolysis to serine synthesis and contributes to maintaining relatively
advantage to cancer cell proliferation and tumor growth.
Right: When PGAM1 is inhibited, 3-PG levels are elevated, which in turn inhibit 6PG
time, 2-PG is decreased to levels below the physiologic concentrations, leadin
metabolic changes result in attenuated cell proliferation and tumor development
The error bars represent mean values ± SD from three replicates of each sample (
Figure S6 and Table S5.
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